Medium materiality6/10
Pfizer price target raised to $33 from $30 at Scotiabank
Why it may matterVerify against the original reporting
Analyst upgrade signals potential near-term upside for Pfizer.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Scotiabank raised Pfizer's target to $33 from $30. Current price is about $27.31, implying potential upside.
- PT raised to 33 from 30
- Current price 27.31
Key facts
- 01
Target: $33
- 02
Posted price: $27.31
- 03
Analyst firm: Scotiabank
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.